vida: extract claims from 2025-12-16-icer-obesity-final-report-glp1-cost-effective-access

- Source: inbox/queue/2025-12-16-icer-obesity-final-report-glp1-cost-effective-access.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -67,3 +67,10 @@ ITIF's 74 million eligible obesity treatment population figure provides the deno
 **Source:** WHO Global Guideline on GLP-1 Medicines for Obesity Treatment, December 2025
 
 WHO explicitly states that current global access and affordability for GLP-1s are 'far below population needs' and that GLP-1s 'should be incorporated into universal health coverage and primary care benefit packages' but acknowledges this is not yet reality anywhere in the developing world. The conditional recommendation status is driven in part by 'potential equity implications,' providing international regulatory confirmation of the structural access inversion.
+
+
+## Supporting Evidence
+
+**Source:** ICER Final Evidence Report, December 2025
+
+ICER report documents the access inversion at policy level: California Medi-Cal (serving lowest-income population) eliminated coverage January 2026 despite 14-0 clinical evidence. Medicare coverage restricted to cardiovascular risk indication, excluding pure obesity. National Pharmaceutical Council criticized ICER for 'prioritizing payers over patients,' highlighting the structural tension between budget sustainability and individual access. The 14-0 clinical verdict combined with simultaneous coverage elimination is the clearest expression of structural misalignment.

inbox/archive/health/2025-12-16-icer-obesity-final-report-glp1-cost-effective-access.md

@@ -7,9 +7,12 @@ date: 2025-12-16
 domain: health
 secondary_domains: []
 format: policy-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
 priority: high
 tags: [glp-1, ICER, cost-effectiveness, obesity, coverage, affordability, Medicaid, Medicare, semaglutide, tirzepatide, budget-impact]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content